Cost-Effectiveness of Alcohol Use Disorder Treatment for Alcohol-Associated Liver Disease
Source:
Key Points
Question Is alcohol use disorder treatment to prevent cirrhosis in patients with alcohol-associated liver disease (ALD) associated with effective and cost-effective outcomes?
Findings In this economic evaluation using a Markov state-transition model to simulate lifetime disease progression and health care costs, after a simulated 16-week treatment with naltrexone and 52 weeks of counseling, decreased liver-related mortality and progression to cirrhosis were observed. A savings of $1126 per person was determined by initiating treatment at stage 3 fibrosis.
Meaning These findings suggest that treating alcohol use disorder with naltrexone and counseling in patients with alcohol-associated liver disease before cirrhosis develops may improve health outcomes while also reducing costs.
- ISSUP members can join Networks to comment – Sign in or become a member